SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dashed line from pills isolated on white
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Welcome to Pennsylvania sign at the Pennsylvania/New York state line along Interstate 90.
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Sanofi's Distribution Center in Quebec, Canada
Rare disease
Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests
Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.
February 2, 2026
 · 
1 min read
 · 
Annalee Armstrong
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Manufacturing
FDA Launches PreCheck Program, Intended To Bring Manufacturers Home
The program will allow for frequent communication with the FDA, giving manufacturers timely input and guidance regarding the design of their facilities.
February 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Drug or medicine dose adjustment. Dose regulation and overdose. Titration of medicine dosage. Overmedication and prescribed dose. Drug rejection.
Complete response letters
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.
February 2, 2026
 · 
1 min read
 · 
Tristan Manalac
Pictured: Amgen's office in Tampa, Florida
Autoimmune disease
Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions
A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data “came in at the lower end of efficacy and expectations.”
February 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Time is money concept. Vector logo of a clock flowing into dollar symbol
Drug Pricing
Opinion: Pricing Transparency Is Coming to the Pharma Industry
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
February 2, 2026
 · 
5 min read
 · 
Joshua R. Mansbach
3d render scene
China
Clinical Trials Are Increasingly Going Global—With China a Main Beneficiary
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
February 2, 2026
 · 
8 min read
 · 
Annalee Armstrong
Creative concept of Left and right brain illustration with colorful on right side isolated on dark background
Psychedelics
Psychedelics Space at a ‘Tipping Point’ as Compass, Definium Gear Up To File for Approval
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
February 2, 2026
 · 
7 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS